Crispr Theraptc (NASDAQ:CRSP) – Oppenheimer Holdings lowered their FY2017 earnings per share (EPS) estimates for shares of Crispr Theraptc in a research note issued on Wednesday. Oppenheimer Holdings analyst L. Cann now expects that the company will post earnings per share of ($2.49) for the year, down from their previous forecast of ($2.43). Oppenheimer Holdings currently has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Crispr Theraptc’s Q4 2017 earnings at ($0.77) EPS, Q1 2018 earnings at ($0.67) EPS, Q2 2018 earnings at ($0.67) EPS, Q3 2018 earnings at ($0.72) EPS, Q4 2018 earnings at ($1.01) EPS, FY2018 earnings at ($3.08) EPS, FY2019 earnings at ($2.71) EPS, FY2020 earnings at ($4.30) EPS and FY2021 earnings at ($5.31) EPS.
Crispr Theraptc (NASDAQ:CRSP) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). Crispr Theraptc had a negative net margin of 466.58% and a negative return on equity of 38.42%. The firm had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. During the same quarter in the prior year, the firm posted ($2.77) EPS. Crispr Theraptc’s quarterly revenue was up 54.2% compared to the same quarter last year. WARNING: “Oppenheimer Holdings Analysts Decrease Earnings Estimates for Crispr Theraptc (CRSP)” was first reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://weekherald.com/2017/11/15/oppenheimer-holdings-analysts-decrease-earnings-estimates-for-crispr-theraptc-crsp.html.
A number of other equities research analysts have also recently weighed in on CRSP. Chardan Capital reiterated a “buy” rating on shares of Crispr Theraptc in a research note on Monday, August 14th. Barclays PLC reiterated a “buy” rating and issued a $29.00 price objective on shares of Crispr Theraptc in a research note on Friday, September 8th. Cann restated a “hold” rating on shares of Crispr Theraptc in a research note on Thursday, November 9th. Finally, SunTrust Banks, Inc. restated a “hold” rating and set a $16.00 price target on shares of Crispr Theraptc in a research note on Friday, November 10th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $21.70.
Shares of Crispr Theraptc (CRSP) opened at $17.46 on Monday. Crispr Theraptc has a 52 week low of $11.63 and a 52 week high of $25.00.
In other news, insider Samarth Kulkarni sold 27,154 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $20.08, for a total transaction of $545,252.32. Following the completion of the sale, the insider now owns 110,893 shares in the company, valued at $2,226,731.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kurt Von Emster sold 34,141 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $19.06, for a total value of $650,727.46. The disclosure for this sale can be found here. Insiders have sold 287,491 shares of company stock valued at $5,690,085 in the last 90 days. Company insiders own 39.98% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Granahan Investment Management Inc. MA raised its stake in shares of Crispr Theraptc by 51.7% during the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock worth $4,713,000 after purchasing an additional 89,839 shares during the last quarter. Allianz Asset Management GmbH purchased a new stake in shares of Crispr Theraptc during the third quarter worth approximately $2,384,000. Adams Street Partners LLC purchased a new stake in shares of Crispr Theraptc during the third quarter worth approximately $1,019,000. Tiff Advisory Services Inc. purchased a new stake in shares of Crispr Theraptc during the third quarter worth approximately $505,000. Finally, Wells Fargo & Company MN raised its stake in shares of Crispr Theraptc by 129.8% during the third quarter. Wells Fargo & Company MN now owns 18,352 shares of the company’s stock worth $328,000 after purchasing an additional 10,365 shares during the last quarter. Institutional investors and hedge funds own 25.61% of the company’s stock.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.